Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

Researchers at The University of Texas MD Anderson Cancer Center have created a comprehensive single-cell map of the tumor ...

Researchers at Weill Cornell Medicine and Birkbeck, University of London, have identified a site where a commonly used ...

Process: Provide long-term appreciation through passive exposure to primarily large-cap US equities. Through O’Shaughnessy’s Canvas Custom Index platform, the investment process uses a risk-based ...

A comprehensive review led by Professors Malgorzata Kloc and Xian Chang Li at the Immunobiology and Transplant Science Center ...

A new review was published in Volume 13 of Oncoscience on May 22, 2026, titled "Adaptor proteins regulating tumor-associated macrophage polarization during cancer progression." ...

UCLA researchers found NDRG1 builds up in old muscle stem cells, slowing repair but boosting survival. Blocking it speeds ...

For decades, fitness culture drew a hard line in the sand. You were either a strength athlete or an endurance athlete. Cardio ...

Individual differences in toddler temperament—including activity, emotionality, sociability, and shyness—are influenced in part by genetic variation. Some of these genetic differences also overlap ...

Detailed price information for Quince Therapeutics Inc (QNCX-Q) from The Globe and Mail including charting and trades.

Dose-optimization data from the Phase 1 study expected Q3 2026 to support Phase 2 proof-of-concept initiation in ADPKD in Q4 2026JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules ...